Group 1 - Ingevity (NGVT) has shown strong performance in the Basic Materials sector, with a year-to-date return of 12.6%, significantly outperforming the sector average of -7.3% [4] - The Zacks Consensus Estimate for Ingevity's full-year earnings has increased by 29% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4] - Ingevity holds a Zacks Rank of 1 (Strong Buy), suggesting it is positioned to outperform the market in the near term [3] Group 2 - Ingevity is part of the Chemical - Specialty industry, which has seen an average loss of 17.5% year-to-date, further highlighting Ingevity's relative strength within its industry [6] - Another stock in the Basic Materials sector, Nouveau Monde Graphite Inc. (NMG), has also outperformed the sector with a year-to-date return of 32.1% and a Zacks Rank of 2 (Buy) [5] - The Mining - Miscellaneous industry, to which Nouveau Monde Graphite belongs, has experienced a year-to-date decline of 18.7%, indicating that both Ingevity and Nouveau Monde Graphite are performing well compared to their respective industries [6]

Core Viewpoint - Ingevity Corporation (NGVT) is exploring strategic alternatives for its Performance Chemicals Industrial Specialties product line, which may include divesting part of its North Charleston site, while excluding certain product lines [1][3]. Group 1: Strategic Review and Financial Performance - The strategic review aims to enhance shareholder value by allowing the company to concentrate on higher growth and margin opportunities, thereby improving earnings and cash flow [2]. - Ingevity anticipates reporting net sales of approximately $1.4 billion and an adjusted EBITDA of around $360 million for fiscal 2024, with free cash flow expected to exceed $40 million [4]. - The company has gained positive momentum, with expectations to deliver adjusted EBITDA modestly above $400 million in fiscal 2025, excluding impacts from the strategic review [5]. Group 2: Market Performance - NGVT's shares have increased by 8.6% over the past year, contrasting with a 17.1% decline in its industry [6].

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true v ...

Ingevity Corporation’s (NGVT) stock looks promising at the moment. Its shares have popped roughly 40% over the past three months. NGVT is expected to benefit from the strategic repositioning of its Performance Chemicals segment, strategic acquisitions and actions to drive growth.We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it is poised to carry the momentum ahead.Let's see what makes NGVT stock an attractive investment option at t ...

For Immediate ReleaseChicago, IL – December 12, 2024 – Today, Zacks Equity Research Axalta Coating Systems Ltd. (AXTA) , Ingevity Corp. (NGVT) and AdvanSix Inc. (ASIX) .Industry: Specialty ChemicalsLink: https://www.zacks.com/commentary/2381908/3-chemical-specialty-stocks-to-watch-amid-industry-challengesThe Zacks Chemicals Specialty industry is mired in challenges from sluggish demand, largely due to the slowdown in Europe and a slow economic recovery in China. Margins of companies in this space also remai ...

A month has gone by since the last earnings report for Ingevity (NGVT) . Shares have added about 14.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ingevity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Ingevity's Earnings Beat Estimates in Q3, Revenues Down ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Ingevity. THIRD QUARTER 2024 EARNINGS PRESENTATION October 30, 2024 2 Use of non-GAAP financial measures: This presentation includes certain non‐GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. Reconciliations of non‐GAAP financial measures to GAAP financial measures are provided within the Appendix to this presentation. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. The company does not ...

Ingevity Corporation (NYSE:NGVT) Q3 2024 Earnings Call October 30, 2024 10:00 AM ET Company Participants John Nypaver - Investor Relations Luis Fernandez-Moreno - Interim Chief Executive Officer Mary Dean Hall - Chief Financial Officer Ed Woodcock - President, Performance Materials Rich White - President, Performance Chemicals Steve Hulme - President, Advanced Polymer Technologies Conference Call Participants Lee Jagoda - CJS Securities Daniel Rizzo - Jefferies John McNulty - BMO Capital Markets Mike Sison ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37586 __________________ ...